Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings, Inc. (LNTH) Healthcare & Pipeline Overview

Lantheus Holdings, Inc. is a global healthcare company specializing in diagnostic and therapeutic products for heart, cancer, and other diseases. Leveraging a diverse portfolio including DEFINITY and PYLARIFY, alongside a robust pipeline and strategic partnerships, it addresses critical clinical needs worldwide, focusing on advanced medical imaging and targeted therapies.

What Is the Investment Thesis for LNTH?

Lantheus Holdings, Inc. presents a compelling profile driven by its specialized portfolio of diagnostic and therapeutic products, particularly in high-demand areas like oncology and cardiology. The company demonstrates strong financial health with an 18.0% profit margin and an impressive 60.5% gross margin, indicating efficient operations and pricing power. A robust Return on Equity (ROE) of 23.5% further highlights its ability to generate profits from shareholder investments. Key growth catalysts include the continued expansion and adoption of PYLARIFY for prostate cancer imaging, which addresses a significant unmet medical need, and the ongoing development of its pipeline assets such as flurpiridaz F 18 for cardiac imaging and PYLARIFY AI for advanced prostate cancer diagnostics. Strategic partnerships with major pharmaceutical and medical technology companies also provide avenues for expanded market reach and accelerated product development. While the debt-to-equity ratio of 51.62 suggests a moderate leverage, the company's strong profitability metrics support its capacity for investment in future growth initiatives and R&D. The focus on innovative radiopharmaceuticals and AI-enhanced diagnostics positions Lantheus to capitalize on evolving healthcare trends.

Based on FMP financials and quantitative analysis

LNTH Key Highlights

• Market capitalization of $6.96B reflects its significant presence in the specialty pharmaceutical and diagnostic imaging sector.
• Profit margin of 18.0% demonstrates strong profitability and efficient management of its revenue streams.
• Gross margin of 60.5% indicates a healthy cost structure relative to its revenue, surpassing many industry benchmarks.
• Return on Equity (ROE) of 23.5% highlights the company's effectiveness in generating profit from shareholders' equity.
• Debt-to-Equity ratio of 51.62 suggests a balanced approach to financing, leveraging debt while maintaining a solid equity base.

Who Are LNTH's Competitors?

LNTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LNTH's Key Strengths?

• Diverse portfolio of established diagnostic and therapeutic products, including market leaders like PYLARIFY and DEFINITY.
• Strong financial performance with high gross (60.5%) and profit (18.0%) margins.
• Robust pipeline of innovative products, including AI-enhanced diagnostics and novel radiotherapeutics.
• Extensive global distribution network and strategic partnerships with key industry players.
• Deep expertise in radiopharmaceutical development and manufacturing.

What Are LNTH's Weaknesses?

• Reliance on a relatively specialized market segment, which can be susceptible to shifts in medical practice or reimbursement policies.
• High R&D costs associated with developing and bringing new radiopharmaceuticals to market.
• Potential for supply chain disruptions given the specialized nature and short half-lives of some radiopharmaceutical components.
• Moderate debt-to-equity ratio (51.62) could limit financial flexibility for large-scale acquisitions without further leverage.

What Could Drive LNTH Stock Higher?

• Potential regulatory approvals for pipeline assets like flurpiridaz F 18, which could open new revenue streams in cardiac imaging.
• Continued expansion of PYLARIFY's market share and adoption rates in prostate cancer diagnostics globally, driving revenue growth.
• Further development and potential commercialization of PYLARIFY AI, enhancing the value proposition of PSMA PET/CT imaging.
• Progress in clinical trials for therapeutic candidates such as 1095 and LMI 1195, indicating future growth opportunities in radioligand therapy.
• Formation of new strategic partnerships or expansion of existing collaborations to broaden product reach and accelerate R&D initiatives.

What Are the Key Risks for LNTH?

• Insider selling — insiders were net sellers of roughly $5.3M recently.
• Clinical trial failures or delays for pipeline products like flurpiridaz F 18 or 1095, which could impact future revenue growth.
• Intense competition in the diagnostic imaging and radiopharmaceutical markets, potentially leading to pricing pressures or market share erosion.
• Regulatory changes or stricter approval processes for new diagnostic and therapeutic agents, increasing development costs and timelines.
• Dependence on third-party manufacturers and suppliers for critical components and radioisotopes, posing potential supply chain risks.
• Reimbursement challenges or changes in healthcare policies that could affect the commercial viability and adoption of Lantheus's products.

What Are the Growth Opportunities for LNTH?

• **Expansion of PYLARIFY and PYLARIFY AI:** The continued adoption and market penetration of PYLARIFY for prostate cancer imaging represents a significant growth driver. As a PSMA-targeted imaging agent, it offers superior visualization for recurrent and metastatic prostate cancer, addressing a critical diagnostic need. The introduction of PYLARIFY AI, an AI-based software for quantitative assessment of PSMA PET/CT images, further enhances its utility and could drive market share by offering standardized, objective analysis. The global prostate cancer diagnostics market is projected to grow substantially, with PSMA PET imaging becoming a standard of care, providing a large and expanding addressable market for Lantheus over the next 5-10 years.
• **Advancement of Flurpiridaz F 18:** Lantheus's investigational product, flurpiridaz F 18, designed to assess blood flow to the heart, holds substantial potential. As a novel PET myocardial perfusion imaging agent, it could offer improved diagnostic accuracy for coronary artery disease compared to existing methods. The cardiovascular diagnostics market remains robust, with a continuous need for non-invasive, highly accurate diagnostic tools. Successful clinical development and regulatory approval of flurpiridaz F 18 could open a new significant revenue stream for Lantheus within the cardiac imaging space, with potential market entry within the next 3-7 years, depending on trial outcomes and regulatory timelines.
• **Therapeutic Pipeline Development:** The company's therapeutic pipeline, including 1095 (a PSMA-targeted iodine-131 labeled small molecule) and LMI 1195 for neuroblastoma tumors, represents a long-term growth opportunity. These assets target specific, high-need oncology indications, aligning with the growing trend of targeted radiotherapeutics. AZEDRA, an existing radiotherapeutic for rare neuroendocrine tumors, provides a foundation in this area. Successful progression of these pipeline candidates through clinical trials and subsequent commercialization could transform Lantheus's revenue mix, adding high-value therapeutic products to its portfolio over a 5-15 year horizon, tapping into the expanding radioligand therapy market.
• **Strategic Partnerships and Collaborations:** Lantheus has established numerous strategic partnerships with companies like NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, and Bayer AG. These collaborations are crucial for expanding product reach, leveraging complementary technologies, and sharing development risks. For instance, partnerships can facilitate global market access for existing products, accelerate the development of pipeline candidates, or integrate Lantheus's products into broader diagnostic and therapeutic platforms. Such alliances provide ongoing growth potential by diversifying revenue streams and strengthening market presence, with benefits continually accruing as new agreements are forged and existing ones mature.
• **Global Market Penetration of Existing Products:** Beyond pipeline products, there remains significant opportunity for increased global market penetration of Lantheus's established diagnostic products, such as DEFINITY, TechneLite, and Cardiolite. As healthcare infrastructure improves in emerging markets and awareness of advanced diagnostic imaging grows, these products can capture new patient populations. Expanding sales channels, securing additional regulatory approvals in new geographies, and educating clinicians on the benefits of these agents can drive sustained, incremental revenue growth. This strategy focuses on maximizing the lifecycle value of proven products, offering a more immediate and consistent growth trajectory over the next 1-5 years.

What Opportunities Does LNTH Have?

• Expansion into new geographic markets for existing and pipeline products, particularly in emerging economies.
• Further integration of AI and digital health solutions to enhance diagnostic accuracy and treatment planning.
• Development and commercialization of new radioligand therapies for various oncology indications.
• Leveraging strategic partnerships to co-develop and co-commercialize novel products, expanding market reach and reducing R&D risk.
• Increasing demand for non-invasive and highly accurate diagnostic imaging techniques due to an aging global population.

What Threats Does LNTH Face?

• Intense competition from other pharmaceutical companies and diagnostic imaging providers.
• Regulatory hurdles and lengthy approval processes for new drug and device candidates.
• Patent expirations on key products, potentially leading to generic competition.
• Changes in healthcare reimbursement policies or pricing pressures from governments and insurers.
• Clinical trial failures or unexpected safety concerns for pipeline products.

What Are LNTH's Competitive Advantages?

• Proprietary diagnostic and therapeutic products with regulatory approvals, such as DEFINITY and PYLARIFY, creating high barriers to entry.
• Strong intellectual property portfolio protecting its specialized radiopharmaceuticals and imaging agents.
• Established global manufacturing and distribution infrastructure for complex radiopharmaceutical products.
• Strategic partnerships with major pharmaceutical and medical technology companies, enhancing market reach and R&D capabilities.
• Expertise in radiopharmaceutical development and AI-enhanced diagnostics, positioning the company at the forefront of medical innovation.

What Does LNTH Do?

Lantheus Holdings, Inc. is a prominent global healthcare company dedicated to the development, manufacturing, and commercialization of innovative diagnostic and therapeutic products. Founded in 1956 and headquartered in North Billerica, Massachusetts, the company has evolved into a key player assisting clinicians in the diagnosis and treatment of heart, cancer, and various other diseases across the globe. Its extensive product portfolio includes DEFINITY, a microbubble ultrasound enhancing agent crucial for cardiac ultrasound exams, and TechneLite, a technetium generator widely used in nuclear medicine. Other diagnostic offerings encompass Xenon-133 for pulmonary function assessment, Neurolite for stroke-related blood flow issues, Cardiolite for cardiac imaging, Thallium-201 for cardiovascular disease detection, and Gallium-67 for identifying infections and cancerous tumors. Beyond diagnostics, Lantheus provides therapeutic solutions such as AZEDRA, a radiotherapeutic for adult and pediatric patients, and RELISTOR for opioid-induced constipation. A significant recent advancement is PYLARIFY, an imaging agent vital for visualizing lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. The company is also actively developing next-generation products like flurpiridaz F 18 for assessing heart blood flow, 1095 as a PSMA-targeted iodine-131 labeled small molecule, and PYLARIFY AI, an AI-based medical device software designed for standardized quantitative assessment of PSMA PET/CT images in prostate cancer. Lantheus serves a broad customer base including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices, further strengthening its market position through strategic partnerships with industry leaders such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, and Bayer AG.

What Products and Services Does LNTH Offer?

• Develop, manufacture, and commercialize diagnostic and therapeutic products for heart, cancer, and other diseases.
• Provide microbubble ultrasound enhancing agents like DEFINITY for cardiac imaging.
• Offer technetium generators (TechneLite) and other nuclear medicine agents for various diagnostic purposes.
• Supply specialized imaging agents like PYLARIFY for prostate cancer visualization.
• Develop radiotherapeutics such as AZEDRA for specific cancer treatments.
• Innovate with AI-based medical device software like PYLARIFY AI for quantitative image assessment.
• Conduct research and development on a pipeline of novel diagnostic and therapeutic candidates.
• Serve a global network of radiopharmacies, hospitals, clinics, and integrated delivery networks.

How Does LNTH Make Money?

• Generate revenue through the sale of proprietary diagnostic imaging agents and radiotherapeutics to healthcare providers.
• Utilize a direct sales force and distribution networks to reach radiopharmacies, hospitals, and clinics worldwide.
• Leverage strategic partnerships for co-development, licensing, and expanded commercialization of products.
• Invest in research and development to create new products and enhance existing ones, securing future revenue streams.
• Monetize intellectual property through patents and regulatory exclusivities for specialized medical products.

What Industry Does LNTH Operate In?

Lantheus Holdings, Inc. operates within the dynamic and specialized 'Drug Manufacturers - Specialty & Generic' industry, a segment of the broader Healthcare sector. This industry is characterized by significant R&D investment, stringent regulatory pathways, and a focus on niche markets with high medical needs. Lantheus is particularly positioned within the radiopharmaceutical and diagnostic imaging sub-sectors, which are experiencing growth driven by an aging global population, increasing prevalence of chronic diseases like cancer and cardiovascular conditions, and advancements in imaging technology. The competitive landscape includes established pharmaceutical giants and specialized biotech firms. Lantheus differentiates itself through its proprietary diagnostic agents like DEFINITY and PYLARIFY, and its pipeline of novel radiotherapeutics and AI-enhanced diagnostic tools. The market trend towards precision medicine and personalized diagnostics further accentuates the value of Lantheus's targeted imaging and therapeutic solutions, allowing it to carve out a distinct and defensible position.

Who Are LNTH's Key Customers?

• Radiopharmacies that prepare and distribute radiopharmaceuticals.
• Hospitals and clinics requiring diagnostic imaging agents and therapeutic radiopharmaceuticals.
• Integrated delivery networks (IDNs) seeking comprehensive healthcare solutions.
• Group practices utilizing specialized diagnostic and therapeutic products.
• Distributors facilitating the supply chain of medical products to various healthcare entities.

Net buyingInsider Activity

Over the past six months, Lantheus Holdings, Inc. insiders filed 27 SEC Form 4 transactions — 9 sales and 18 purchases. On net that is roughly 145K shares acquired (about $5.3M) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project Lantheus Holdings, Inc. revenue of about $1.47B for fiscal 2026, with EPS near $5.35. The estimate reflects 11 contributing analysts.

F-Score 5/9Financial Health

Lantheus Holdings, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.78 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 24%Key Financial Metrics

Return on equity for Lantheus Holdings, Inc. stands at 24.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.9%, showing how much profit it generates from its asset base. LNTH trades at a trailing price-to-earnings ratio of 23.71, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.0%, the inverse of the P/E and a quick read on earnings relative to price.

Lantheus Holdings, Inc. (LNTH) Valuation Context

Valued at $6.96B, LNTH is classified as a mid-cap stock. Relative to its peer group, LNTH's quantitative score of 91/100 is above the peer average of 64/100.

Company Profile

Lantheus Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Bedford, US. The company is led by CEO Mary Anne Heino. LNTH has traded publicly since 2015.

LNTH Financials

LNTH Latest News

LNTH Analyst Consensus

LNTH MoonshotScore

Latest Lantheus Holdings, Inc. Analysis

LNTH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources